Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
20.92
+0.33 (1.60%)
Aug 18, 2026, 11:22 AM EDT - Market open
Cullinan Therapeutics Employees
Cullinan Therapeutics had 109 employees as of December 31, 2025. The number of employees decreased by 2 or -1.80% compared to the previous year.
Employees
109
Change (1Y)
-2
Growth (1Y)
-1.80%
Revenue / Employee
n/a
Profits / Employee
-$1,911,404
Market Cap
1.35B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 109 | -2 | -1.80% | 109 | 0 |
| Dec 31, 2024 | 111 | 26 | 30.59% | 111 | 0 |
| Dec 31, 2023 | 85 | 23 | 37.10% | 85 | 0 |
| Dec 31, 2022 | 62 | 31 | 100.00% | 62 | 0 |
| Mar 31, 2022 | 37 | 13 | 54.17% | 37 | 0 |
| Dec 31, 2021 | 31 | 7 | 29.17% | 31 | 0 |
| Sep 30, 2021 | 33 | 15 | 83.33% | 33 | 0 |
| Jun 30, 2021 | 28 | 11 | 64.71% | 28 | 0 |
| Mar 31, 2021 | 24 | 7 | 41.18% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immatics | 678 |
| MeiraGTx Holdings | 409 |
| EyePoint | 214 |
| Monte Rosa Therapeutics | 173 |
| Alpha Tau Medical | 121 |
| Inhibrx Biosciences | 110 |
| Vor Biopharma | 76 |
CGEM News
- 1 day ago - Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS - TheFly
- 1 day ago - Cullinan Therapeutics price target raised to $47 from $46 at Clear Street - TheFly
- 12 days ago - Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c) - TheFly
- 12 days ago - Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 12 days ago - Cullinan Therapeutics Quarterly report: Q2 2026 - Filings
- 12 days ago - Cullinan Therapeutics Earnings release: Q2 2026 - Filings
- 20 days ago - Cullinan Therapeutics price target raised to $39 from $38 at BTIG - TheFly
- 21 days ago - Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA - TheFly